T0	Participants 58 120	patients with hepatitis C virus-related chronic liver disease.
T1	Participants 285 351	101 patients with hepatitis C virus-related chronic liver disease.
T2	Participants 360 480	Forty-nine patients were assigned to receive UDCA (450 mg/day) over a period of 6 months and 52 to receive no treatment.
T3	Participants 970 1021	patients who fail to respond to interferon therapy.